WO2006051997A1 - システインジオキシゲナーゼ誘導剤 - Google Patents
システインジオキシゲナーゼ誘導剤 Download PDFInfo
- Publication number
- WO2006051997A1 WO2006051997A1 PCT/JP2005/020985 JP2005020985W WO2006051997A1 WO 2006051997 A1 WO2006051997 A1 WO 2006051997A1 JP 2005020985 W JP2005020985 W JP 2005020985W WO 2006051997 A1 WO2006051997 A1 WO 2006051997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cystine
- dioxygenase
- chain amino
- cysteine
- metabolism
- Prior art date
Links
- 239000000411 inducer Substances 0.000 title claims abstract description 36
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 108010028143 Dioxygenases Proteins 0.000 title claims abstract description 18
- 102000016680 Dioxygenases Human genes 0.000 title claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 40
- 230000004060 metabolic process Effects 0.000 claims abstract description 24
- 230000002159 abnormal effect Effects 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 73
- 108010039724 Cysteine dioxygenase Proteins 0.000 claims description 53
- 102000015295 Cysteine Dioxygenase Human genes 0.000 claims description 51
- 230000014509 gene expression Effects 0.000 claims description 42
- 229960003067 cystine Drugs 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 27
- 235000018417 cysteine Nutrition 0.000 claims description 24
- 230000006371 metabolic abnormality Effects 0.000 claims description 17
- 230000006698 induction Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 12
- 230000001629 suppression Effects 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000006806 disease prevention Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 9
- 102000004020 Oxygenases Human genes 0.000 claims 1
- 108090000417 Oxygenases Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 17
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 101150065372 CDO gene Proteins 0.000 description 25
- 108020004999 messenger RNA Proteins 0.000 description 23
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 102000009618 Transforming Growth Factors Human genes 0.000 description 16
- 108010009583 Transforming Growth Factors Proteins 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 6
- -1 tripeptide Proteins 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000737778 Homo sapiens Cysteine dioxygenase type 1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150045515 O gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 101150027769 cda gene Proteins 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- RQGPLDBZHMVWCH-UHFFFAOYSA-N pyrrolo[3,2-b]pyrrole Chemical compound C1=NC2=CC=NC2=C1 RQGPLDBZHMVWCH-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an inducer of cysteine dioxygenase (CDO) containing a branched chain amino acid, a pharmaceutical composition containing the same, and a food or drink containing the branched chain amino acid.
- CDO cysteine dioxygenase
- Cystin dioxygenase is mainly expressed in the liver and is one of the major enzymes in cystine metabolism and plays an important role in the quantitative regulation of sulfur-containing amino acids in vivo. It is known to fulfill. Chronically elevated cysteine levels are known to function as neurotoxins that are excitable for neurons (McFadden et al., “Toxicology”, Ireland), 1 9 9 6th, 1 1 1st, P. 4 3— 6 5). On the other hand, Parkinson's disease (Steventon et al., “Neurology”, (USA), 1 9 8 9th, Vol. 39, P.
- Tumor growth factor] 3 (TG F ⁇ ), one of the inflammatory site ins, is also associated with multiple sclerosis, Parkinson's disease, AIDS dementia, Alach It has been suggested that neurodegenerative diseases such as Imah's disease are related to the progression of the disease, but the details are not clear (Pratt et al., “Site Force In & Growth Factor Leviuse (Cytokine Growth Factor Rev.) ", (UK), 1 997, 8th (4), P. 2 6 7-2 9 2).
- An object of the present invention is to provide an excellent cysteinoxygenase (CDO) inducer.
- the object of the present invention is to treat a disease caused by a cystine metabolism disorder (a neurological disease such as Parkinson's disease or Hallervorden-Spatz disease) and a drug for preventing or preventing cysteine metabolism abnormalities.
- a cystine metabolism disorder a neurological disease such as Parkinson's disease or Hallervorden-Spatz disease
- a drug for preventing or preventing cysteine metabolism abnormalities to provide ingredients.
- the present inventors have found that branched-chain amino acids have an excellent CDO gene expression-inducing action, and further, the pathogenesis of various diseases. It was also found that the inflammatory cytokine TGF] 3 involved in the progression suppresses the expression of CDO, and that branched-chain amino acids release the suppression, thereby completing the present invention. That is, the present invention provides a branched chain buffer. Provided is a CDO inducer comprising a mino acid.
- the present invention also provides a pharmaceutical product for treating and / or preventing a disease caused by an abnormal cystine metabolism (a neurological disease such as Parkinson's disease or Hal lervorden-Spatz disease) characterized by containing the above-mentioned CDO inducer.
- the present invention provides an active ingredient of a food or drink for improving metabolic disorders.
- a therapeutic or prophylactic agent for diseases caused by abnormal cystine metabolism comprising the cystine dioxygenase inducer according to any one of [1] to [4];
- the disease caused by abnormal cysteine metabolism is selected from the group consisting of Parkinson's disease, Al-Haima disease, and rheumatoid arthritis [5]
- a food and drink for improving cystine metabolism disorder characterized by containing a branched chain amino acid
- a method for inducing cysteine dioxygenase comprising administering an effective amount of a branched chain amino acid to an administration subject;
- a method for treating or preventing a disease caused by abnormal cysteine metabolism comprising administering an effective amount of a cysteine dioxygenase-inducing agent containing a branched chain amino acid to a subject of administration;
- FIG. 1 shows the suppression of mRNA expression of CDO gene by TGF] 3.
- Figure 2 shows the induction of mRNA expression of CDO gene by branched chain amino acids. It is a figure.
- FIG. 3 is a diagram showing the mRNA expression induction action of a branched chain amino acid-specific CDO gene.
- FIG. 4 is a diagram showing (A) enhancement of CDO gene promoter activity by branched chain amino acids, (B) suppression of CDO gene promoter activity by TGF and enhancement effect by BCAA.
- FIG. 5 is a diagram showing the mRNA expression induction effect of CDO gene by branched chain amino acids in a cirrhosis model rat.
- the branched chain amino acid in the present invention refers to those containing at least one of isoleucine, valine, and oral isocyanic branched chain amino acids, each of which may be used alone or in combination of two or more. It may be a combination of these, or may include all three types.
- Induction of CDO in the present invention refers to an action of increasing the amount of CDO in vivo, particularly CDO in the liver, and is not particularly limited in its mechanism, but induces the expression of CDO gene and / or It is preferably an action that enhances or activates transcription of the CD O gene promoter. Furthermore, since TGF i3 suppresses the expression of the CDO gene or suppresses transcription from the CDO gene promoter, suppression of the action of TGF / 3 is also included in the induction of CDO.
- the CDO gene is a gene having a base sequence represented by ⁇ -001801 or its equivalent (for example, a variant including SNP and haplotype) in NCBI Reference Sequences (RefSeq) in humans, for example. Or a mammalian ortholog, etc., which encodes a protein with an Enzyme Commission Number force S, EC 1 ⁇ 13.11.20, as defined by the International Biochemical Union.
- the branched chain amino acid which is an active ingredient of the CDO inducer of the present invention, is always used. It is not necessary to be used as a free amino acid, and it may be used in the form of a salt or an ester that can be hydrolyzed in vivo (for example, an ester with an alcohol that can be used as a prodrug of a pharmaceutical product). Good.
- the salt form include acid addition salts and salts with bases, and it is preferable to select a salt of a branched chain amino acid that is acceptable as a pharmaceutical or a food or drink.
- acids that are added to branched chain amino acids to form salts that are acceptable as pharmaceuticals or foods and drinks include inorganic salts such as hydrogen chloride, hydrogen bromide, sulfuric acid, and phosphate, acetic acid, lactic acid, citrate, Organic acids such as tartaric acid, maleic acid, fumaric acid or monomethyl sulfuric acid can be mentioned.
- bases acceptable as pharmaceuticals or foods and drinks of branched chain amino acids include, for example, metal hydroxides or carbonates such as sodium, potassium and calcium, salts with inorganic bases such as ammonia, ethylenediamine And salts with organic bases such as propylenediamine, ethanolamine, monoalkyl / reethanolamine, dialkylethanolamine, diethanolamine, and triethanolamine.
- branched chain amino acids or peptides in which a branched amino acid other than a branched chain amino acid and a branched chain amino acid are peptide-bonded (eg, dipeptide, tripeptide, oligopeptide, etc.)
- peptides are also branched chain amino acids as referred to in the present invention.
- the branched chain amino acid is in the form of a peptide
- the content of the branched chain amino acid in the peptide is preferably 10% or more, more preferably 25% or more, and still more preferably 50% or more.
- amino acids other than branched chain amino acids include glycine, alanine, serine, threonine, aspartate, glutamate, asparagine, gnoretamine, lysine, hydroxylysine, arginine, cysteine, cystine, methionine, Examples include phenylalanine, tyrosine, tryptophan, histidine, proline, and 4-hydroxyproline.
- any of L-integral, D-form, and DL-form can be used. However, L integration is desirable from the viewpoint of natural existence.
- the C D O inducer of the present invention may be composed only of a branched chain amino acid, but may contain a pharmaceutical carrier described later, or may be contained in a general food or drink.
- the CDO inducer of the present invention preferably contains about 0.1 1 to 10 g of branched chain amino acids, more preferably about 0.1 to 10 g, and even more preferably 1 to 10 g. Degree.
- the C D O inducer of the present invention can be administered orally, intravenously, subcutaneously, or intramuscularly, but oral administration is preferred because of its simplicity.
- the dose varies depending on the subject to be administered, but is usually 0.1 to 30 g Z k g Z days.
- parenteral administration such as infusion administration, injection administration (intravenous administration), etc.
- the preferred dosage (ingestion amount) for oral administration is as follows. About 10 to 20 times of the range can be administered.
- the CDO inducer of the present invention can be formulated by a conventional method.
- the form of the preparation is tablets, granules, fine granules, powders, capsules, solids such as chupuls, solutions such as solutions and syrups, or creams, suppositories, injections, sprays , Etc.
- Examples of the carrier for the preparation include lactose, glucose, D-mannitol, starch, crystalline cellulose, calcium carbonate, kaolin, starch, gelatin, hydroxypropyl senorelose, hydroxypropinoremethizolecenorelose, polyvinyl pyrrolopyrrole Don, Ethanol / Les, Canolepoxymethyl senorelose, Canolepoxy methinolece Norellose chanoleum salt, Magnesium stearate, Talc, Acetinole Cellulose, Sucrose, Titanium oxide, Benzoic acid, Paraoxybenzoate ester, De Sodium hydroacetate, gum arabic, tragacanth, methylsenololose, egg yolk, surfactant, sucrose, simple syrup, citrate, distilled water, ethanolate, glycerin.
- Propyleneglycone, macrogonore, phosphate There are sodium monohydrogen, sodium dihydrogen phosphate, sodium phosphate, bud sugar, sodium chloride, phenol, thimerosal, paraoxybenzoate, sodium hydrogen sulfite, etc. Used in combination with CDO inducers.
- the C D O inducer of the present invention is useful for mammals (eg, mice, rats, hamsters, rabbits, cats, dogs, sushi, Hedges, monkeys, humans, etc.).
- mammals eg, mice, rats, hamsters, rabbits, cats, dogs, sushi, Hedges, monkeys, humans, etc.
- the administration form to animals other than humans may be addition to feed.
- the C D O inducer of the present invention can be formulated into various pharmaceutical preparations to be developed in the future. Methods that will be developed in the future can be used as appropriate.
- the C D O inducer of the present invention in the preparation form exemplified above should contain an effective amount of the above-mentioned components to exert a medicinal effect.
- an effective amount of the above-mentioned ingredients should be contained to have a medicinal effect is also applicable to the use in medicines and foods and drinks described below.
- the C D O inducer of the present invention is useful for patients with diseases caused by abnormal cysteine metabolism.
- diseases caused by abnormal cysteine metabolism include neurological diseases such as Parkinson's disease, Alzheimer's disease, Hal lervorden- Spatz disease, rheumatoid arthritis, motor neuron diseases (for example, amyotrophic lateral cords). Sclerosis) and delayed food hypersensitivity.
- the C D O inducer of the present invention can be used as a pharmaceutical product. Since the active ingredient is an amino acid, it is excellent in safety and can be used easily. When used as a medicine, the form is not particularly limited, and the above preparation may be used as it is.
- the present invention provides a therapeutic or prophylactic agent for diseases caused by abnormal cystine metabolism, which contains a CDO inducer.
- the treatment and / or prevention of a disease caused by abnormal cysteine metabolism also includes suppressing the occurrence / progress of the disease caused by abnormal cysteine metabolism.
- a therapeutic or prophylactic agent or other pharmaceutical composition for diseases caused by abnormalities in cystine metabolism such as Parkinson's disease or Hallervorden-Spatz disease
- cystine metabolism such as Parkinson's disease or Hallervorden-Spatz disease
- 1 preparation it is preferable to contain about 0.1 to 10 g of branched chain amino acids, more preferably about 0.1 to 10 g, and still more preferably about 1 to 10 g.
- the therapeutic or prophylactic agent for diseases caused by cysteine metabolism abnormalities according to the present invention it can be administered orally, intravenously, subcutaneously, or intramuscularly. However, oral administration is preferred because of its simplicity.
- the dose varies depending on the patient's symptoms, age, and method of administration, but is usually 0.1 to 3 0 ⁇ 1 ⁇ ⁇ "days.
- parenteral administration such as infusion administration, injection administration (intravenous administration), etc.
- the preferred dosage (ingestion amount) for oral administration is as follows. About 10 to 20 times of the range can be administered.
- the present invention also provides a food or drink characterized by containing a branched chain amino acid.
- the food / drink exhibits an effect of inducing cysteine dioxygenase, an effect of enhancing the expression of cysteine dioxygenase gene, and an effect of suppressing the action of TGF] 3, and is therefore effective as a food / drink for improving cystine metabolism abnormality.
- Examples of the branched chain amino acids contained in the food / beverage products of the present invention include the same as those mentioned above for the C D O derivative.
- the form is not particularly limited, and the food and drink may contain only the amount necessary to exert the CDO inducing effect of the branched chain amino acid.
- the food and drink may include animal feed.
- the intake is usually 0.1 to 30 g / kg Z days, although it varies depending on the type, age, and method of intake.
- the food and drink of the present invention is useful for mammals (eg, mouse, rat, hamster, usagi, cat, inu, ushi, hidge, monkey, human etc.).
- mammals eg, mouse, rat, hamster, usagi, cat, inu, ushi, hidge, monkey, human etc.
- the active ingredient is an amino acid
- it is excellent in safety and can be easily used in the form of food and drink.
- foods and drinks can be mixed with juice, milk, confectionery, jelly and the like.
- Such foods and drinks are also included.
- These health functional foods are labeled foods and drinks that are used to improve cystine metabolism abnormalities, especially for specific health use. Foods etc. are also included.
- the food-drinks of this invention when using the food-drinks of this invention as a food supplement etc., it can prepare in forms, such as a tablet, a capsule, a powder, a granule, a suspension agent, a chewable agent, a syrup agent, for example.
- the expression level of CD ⁇ mRNA decreased depending on the concentration of TGF (Fig. 1).
- Hep G 2 cells were seeded on a collagen-coated 60 mm dish and cultured overnight in DMEM medium containing 10% FBS until reaching about 70% confluence. The medium was removed, washed with PBS, replaced with serum-free DMEM medium containing 0.1% BSA, and cultured for 2 hours. Next, after removing the medium and washing with PBS, the medium was replaced with an amino acid-deficient medium in which only methionine was added to amino acid-free DMEM at a concentration of 3 O mg / L and cultured for 2 hours.
- BCAA branched chain amino acid
- B CAA enhances CDO mRNA expression by TGF] 3 treatment.
- the CDO mRNA level which was also observed under physical conditions and decreased by TGF treatment, recovered to near the control level by adding BCAA (Fig. 2).
- Example 3 Induction of mRNA expression of CD 0 gene by branched chain amino acid in human hepatoma cell line Hep G 2 cells
- Hep G 2 cells are cultured under the same conditions as in Example 2.
- 3 O mg / L methionine, 2 mM BCAA mixture, or any one of individual branched chain amino acids, phenylalanin, and cysteine The cells were cultured for 16 hours in an amino acid-deficient DMEM medium containing.
- Activation of mT OR is via phosphorylation of S 6 K 1 and 4 E—B P 1: it accelerates the translation initiation stage of mRNA and enhances gene expression at the protein level. Therefore, we investigated the involvement of mT O R in the effect of B C A A observed in the regulation of CD0 gene expression.
- Hep G 2 cells were cultured in a medium containing only methionine for 2 hours, they were treated with 25 ng / m 1 of rapamycin after 1 hour and a half, and 30 minutes later, 2 mM BCAA was added and cultured for 16 hours. As a result, the increase in the mRNA expression level of CDO by B CAA was not suppressed by rapamycin treatment (Fig. 3 (B)).
- a genomic sequence from about 2.5 kb upstream to about 2.3 kb downstream of the transcription start site of the human CDO gene is inserted into the commercially available luciferase reporter gene pGL 3 basicvector P romeg a
- the reporter gene pGL3-CD04 integrated into the cloning site of Madison, Wis.) was constructed and transfected into Hep G2 cells.
- C DO specific primer sense primer sequence: 5'-GAG AACGT CAG C CACACAG-3 '(SEQ ID NO: 1)
- antisense primer sequence 5'-TTG CT GT GGAATGT CATGG-3' (SEQ ID NO: 2)
- the CD O mRNA expression level was quantified. Quantitative results were expressed as a percentage, with the average value of normal rat being 100%, with the value corrected using GAP DH as an internal standard (Fig. 5). In the normal diet group of the cirrhosis model rat, the CD O mRNA mRNA expression level in the liver decreased to 50% or less of the normal rat, but in the BCAA diet group, it recovered to the normal level.
- BC AA is effective in restoring the decreased CDO gene expression level in the liver of cirrhosis model rat.
- the inducer of cystine dioxygenase (CDO) containing a branched chain amino acid provided by the present invention is useful for the treatment and / or prevention of diseases caused by abnormal cysteine metabolism.
- this inducer since this inducer has an amino acid as an active ingredient, it is highly safe and has few side effects, so it is advantageous not only for pharmaceuticals but also for food and drink.
- the inducer of cysteine dioxygenase comprising a branched chain amino acid provided by the present invention has excellent cysteine dioxygenase-inducing activity.
- the pharmaceutical composition of the present invention contains amino acid as an active ingredient, it is highly safe and has few side effects. Therefore, it can be administered for a long period of time, and is a disease caused by abnormal cysteine metabolism (Parkinson's disease). Can be advantageously used for the treatment and prevention or prevention of neurological diseases such as Hallervorden-Spatz disease.
- the food and drink for improving cystine metabolism abnormality of the present invention also uses amino acid as an active ingredient, it is highly safe and can be consumed over a long period of time. It is effective to prevent it.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004324700 | 2004-11-09 | ||
JP2004-324700 | 2004-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006051997A1 true WO2006051997A1 (ja) | 2006-05-18 |
Family
ID=36336659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020985 WO2006051997A1 (ja) | 2004-11-09 | 2005-11-09 | システインジオキシゲナーゼ誘導剤 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006051997A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0276813A (ja) * | 1988-05-06 | 1990-03-16 | Ajinomoto Co Inc | 神経変性疾患の治療薬 |
JPH05339148A (ja) * | 1992-05-28 | 1993-12-21 | T Knight Albert | 血液脳関門を通過する物質 |
WO2002060431A1 (fr) * | 2001-01-30 | 2002-08-08 | Ajinomoto Co., Inc. | Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires |
JP2004292437A (ja) * | 2003-03-10 | 2004-10-21 | Masami Moriyama | 異常プリオン蛋白質の増殖の抑制方法 |
-
2005
- 2005-11-09 WO PCT/JP2005/020985 patent/WO2006051997A1/ja not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0276813A (ja) * | 1988-05-06 | 1990-03-16 | Ajinomoto Co Inc | 神経変性疾患の治療薬 |
JPH05339148A (ja) * | 1992-05-28 | 1993-12-21 | T Knight Albert | 血液脳関門を通過する物質 |
WO2002060431A1 (fr) * | 2001-01-30 | 2002-08-08 | Ajinomoto Co., Inc. | Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires |
JP2004292437A (ja) * | 2003-03-10 | 2004-10-21 | Masami Moriyama | 異常プリオン蛋白質の増殖の抑制方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5812565B2 (ja) | アミノ酸組成物 | |
Prasad | Discovery of zinc for human health and biomarkers of zinc deficiency | |
KR20130137719A (ko) | 알콜대사를 완화하고 알콜유도성 질환의 위험을 감소하기 위한 조성물 | |
JP5074661B2 (ja) | 肝癌発生・進展抑制剤 | |
US20170027897A1 (en) | mTORC1 MODULATION BY AMINO ACIDS AND USES THEREOF | |
US20080038321A1 (en) | Prophylactic/therapeutic compositions for liver diseases | |
US20220241259A1 (en) | Compositions and methods using trigonelline and vitamins for preventing or treating conditions or disorders in skeletal muscle | |
US4987123A (en) | Compositions useful for the treatment and/or prevention of hepatic disorders, and their pharmaceutical use | |
TW200924744A (en) | Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition | |
US20220241266A1 (en) | Compositions and methods using trigonelline and high protein for preventing or treating conditions or disorders in skeletal muscle | |
JPWO2002034257A1 (ja) | 中枢神経系の疲労回復又は予防剤及び疲労回復又は予防のための食品 | |
JPWO2007029730A1 (ja) | 老人性貧血を防止又は治療するためのアミノ酸組成物 | |
JP7503179B2 (ja) | インスリン抵抗性改善用組成物 | |
JP2022538584A (ja) | 骨格筋における状態又は障害を予防又は治療するための、トリゴネリン及びミネラルを使用する組成物及び方法 | |
WO2007060924A1 (ja) | 膵β細胞保護剤 | |
TW201113023A (en) | Enhancer of activity of nucleic acid analogue | |
WO2006051997A1 (ja) | システインジオキシゲナーゼ誘導剤 | |
JP7068942B2 (ja) | トリペプチド含有組成物 | |
JP4300753B2 (ja) | 貧血抑制剤及び食欲抑制剤 | |
WO2022080249A1 (ja) | 炎症性腸疾患の予防又は改善剤 | |
EP1475090A1 (en) | Drugs for mitochondrial diseases | |
TW202402190A (zh) | 包含源自乳清蛋白的肽的生長促進用組合物 | |
WO2024095905A1 (ja) | アミロイドβ蓄積抑制用組成物 | |
KR960016569B1 (ko) | 알라닌 및 글루타민 함유 식품 조성물 | |
JP2009084197A (ja) | 内因性オピオイドペプチドの血中分泌促進用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 05806654 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |